Month: April 2025

Work On Ten (10) Buildings Will Generate Over 3 Megawatt Hours of Renewable Solar Power Annually RONKONKOMA, N.Y., April 22, 2025 (GLOBE NEWSWIRE) — SUNation Energy, Inc. (Nasdaq: SUNE), a leading provider of sustainable solar energy and backup power solutions for households, businesses, and municipalities, has signed separate Letters of Intent (LOI) with Energy Systems Group (ESG), an award-winning energy services company, for the deployment of over 2.35 MWs of solar power at two school districts on Long Island. Collectively, these installations are designed to deliver 3 megawatt hours (MWHs) of clean solar energy across 10 buildings that would offset a substantial majority of each district’s energy needs. The projects under LOI are:A total of seven (7) schools and facility buildings within a prominent school district on Long...

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, April 22, 2025 (GLOBE NEWSWIRE) — Liberty Gold Corp. (TSX:LGD; OTCQX: LGDTF) (“Liberty Gold” or the “Company”) is pleased to announce that it has closed its previously announced “bought deal” public offering of 69,699,200 units of the Company (the “Units“) at a price of C$0.33 per Unit for gross proceeds of C$23,000,736, which included the exercise, in full, of the Underwriters’ over-allotment option (the “Offering”). The Offering was conducted by Canaccord Genuity Corp. (“Canaccord Genuity”), as sole bookrunner, and BMO Capital Markets, as co-lead underwriter with Canaccord Genuity, and included Paradigm Capital Inc., Desjardins Securities Inc. and Ventum Financial Corp. (collectively, the...

Key HighlightsDigital Asset Platform Introduction: Matador is preparing to launch its Digital Asset Platform, enabling the inscription of digital art onto physical gold. The platform integrates precious metals-based art with blockchain infrastructure using Bitcoin Ordinals, a protocol built on the Bitcoin Network. “Grammies” – Digital Gold Collectibles: The first product, “Grammies,” consists of 1-gram gold units with digital inscriptions recorded on Bitcoin. These units are tradable and transferable via Ordinals-compatible Bitcoin wallets and can be converted into physical gold-based artwork. Timing and Market Context: Gold has recently exceeded ~USD$3,400/oz, providing a favorable environment for the Digital Gold Product launch, particularly as investors explore alternative stores of value amid global macroeconomic uncertainty. Team...

SEATTLE, April 22, 2025 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced that the United States Patent and Trademark Office (USPTO) has granted a new patent (U.S. Patent No. 12,275,684) directed to enteric oral formulations comprising (Z)-endoxifen as well as methods of treating subjects with those oral formulations. This newly granted patent further fortifies Atossa’s intellectual property portfolio surrounding its proprietary (Z)-endoxifen formulations, encompassing novel compositions and methods related to (Z)-endoxifen, a potent Selective Estrogen Receptor Modulator (SERM). Specifically, the patent covers enteric oral formulations of (Z)-endoxifen and salts thereof as well as...

In a survey representative of the general U.S. adult population, 1.26 percent of respondents – equivalent to about 3 million people – reported having received a medical diagnosis of babesiosis during their life-time; CDC data imply only about 73,000 people in that category. At the time they replied to the survey, 3.7 percent of respondents – equivalent to about 9.9 million people – reported they had been experiencing fatigue, a common symptom of babesiosis, for six months or longer.WASHINGTON, April 22, 2025 (GLOBE NEWSWIRE) — 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced findings that the actual burden of babesiosis in the United States (U.S.) may be significantly higher than Centers...

CHICAGO, April 22, 2025 (GLOBE NEWSWIRE) — GCM Grosvenor (Nasdaq: GCMG), a leading global alternative asset management solutions provider, announced the final close of its Infrastructure Advantage Fund II (“IAF II” or the “Fund”) was held on March 31, 2025, securing $1.3 billion in commitments, a substantial increase over its predecessor, “Fund I”, which closed in 2020 at $893 million.    GCM Grosvenor’s Infrastructure Advantage Strategy focuses on partnership with organized labor and other stakeholders to invest in infrastructure projects with long-term community and economic benefits. Similar to Fund I, IAF II will focus on building a diverse portfolio of assets across infrastructure sectors including transportation, energy transition, and digital infrastructure. The Fund attracted a broad group of 58 investors...

A Scientific Breakthrough in Skin Renewal: A Clinically Proven Dual-Action, Slow-Release, Overnight Skin Renewal Cream for a Resurfaced, Smoother, and More Even-Looking ComplexionNEW YORK, April 22, 2025 (GLOBE NEWSWIRE) — Obagi Medical (“Obagi”), the fastest-growing professional skincare brand in the U.S. in 2024* and a subsidiary of Waldencast plc, (NASDAQ: WALD) (“Waldencast”), proudly introduces its latest breakthrough: Retinol + PHA Refining Night Cream. This advanced formulation is engineered to optimize skin renewal by leveraging the efficacy of Entrapped Retinol with the scientifically proven gentle exfoliating properties of Polyhydroxy Acid (PHA) Gluconolactone. This synergistic combination enhances cell turnover while reinforcing the skin barrier, resulting in a visibly refined, smoother, and more even...

BAYONNE, N.J., April 22, 2025 (GLOBE NEWSWIRE) — BCB Bancorp, Inc. (the “Company”), (NASDAQ: BCBP), the holding company for BCB Community Bank (the “Bank”), today reported a net loss of $8.3 million for the first quarter of 2025, compared to net income of $3.3 million in the fourth quarter of 2024, and net income of $5.9 million for the first quarter of 2024. Its loss per diluted share for the first quarter of 2025 was ($0.51), compared to earnings per diluted share of $0.16 in the preceding quarter and $0.32 in the first quarter of 2024. The Company also announced that its Board of Directors declared a regular quarterly cash dividend of $0.16 per share. The dividend will be payable on May 21, 2025 to common shareholders of record on May 7, 2025. “Our first-quarter loss was primarily driven by a $13.7 million specific reserve tied...

AUSTIN, Texas, April 22, 2025 (GLOBE NEWSWIRE) — EZCORP, Inc. (“EZCORP” or the “Company”) (NASDAQ: EZPW), a leading provider of pawn transactions in the United States and Latin America, will issue second quarter fiscal 2025 results (period ended March 31, 2025) on Monday, April 28, 2025, after the market close. The Company will host a webcast and conference call at 9:00 a.m. Eastern time on Tuesday, April 29, 2025, to discuss its results. The presentation slides will be posted to the Investor Relations section of its website after the market close on Monday, April 28, 2025. Date: Tuesday, April 29, 2025Time: 9:00 a.m. Eastern timeDial-in registration link: https://registrations.events/direct/NTM1088399 Live webcast registration link: https://edge.media-server.com/mmc/p/hqptihjy A replay of the conference call will be available...

Conference attendees will get first look at new data that supports the potential of ERNA-101 to boost anti-tumor immunity in ovarian cancer CAMBRIDGE, Mass., April 22, 2025 (GLOBE NEWSWIRE) — Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that new data will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago. The study explored the technology behind Ernexa’s lead cell therapy product, ERNA-101, which uses specially engineered cells to deliver treatment directly to ovarian tumors. By secreting immune-stimulating cytokines, this cell therapy treatment aims to reshape the tumor microenvironment and enhance anti-tumor immune responses, fighting off the cancer. The study was led by Michael...